West Fountain Capital Management Limited
Overview
West Fountain Capital Management was established as part of the global expansion strategy of Shenzhen Capital Group Company Limited. It functions as the overseas management company for the West Fountain USD/RMB Parallel Funds, which it co-manages with the domestic firm Wanrong Hongtu. The funds focus on venture capital investments and cross-border mergers and acquisitions in high-tech, high-growth companies in international markets, including the United States, Germany, Israel, and Japan. The firm's investment thesis is to "Invest in the smartest company and solve the most difficult problems".
Portfolio Companies
9
Website
westfountain.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Regend Therapeutics | Mar 2022 | Series B | - |
| TytoCare | Mar 2021 | Series D Extension | - |
| Exceeds AI | Dec 2020 | Seed | Co-investor |
| 云扩科技 | Mar 2020 | Series B | - |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.